drugset / Trial / NCT06674265
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Phase 1
Recruiting
10 enrolled
Marzieh Ebrahimi
Iran University of Medical Sciences · collabRoyan Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma. Is the injection of allogenic nk cells safe in patients with R/R high-risk neuroblastoma? Is the injection of allogenic nk cells effective in patients with R/R high-risk neuroblastoma? We will compare the NK cell administration group with a control group that receives conventional treatment to determine whether the intervention is safe and effective
Timeline
- Start
- 2024-11-10
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allogenic NK cells | Cell therapy | 5e+06 cells/kg | Intravenous |